Plus Therapeutics Inc (PSTV)
1.18
-0.02
(-1.67%)
USD |
NASDAQ |
Nov 22, 16:00
1.20
+0.02
(+1.69%)
Pre-Market: 20:00
Plus Therapeutics Research and Development Expense (Quarterly): 2.858M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.858M |
| June 30, 2024 | 2.773M |
| March 31, 2024 | 2.763M |
| December 31, 2023 | 2.794M |
| September 30, 2023 | 2.493M |
| June 30, 2023 | 1.42M |
| March 31, 2023 | 2.983M |
| December 31, 2022 | 2.138M |
| September 30, 2022 | 2.945M |
| June 30, 2022 | 2.831M |
| March 31, 2022 | 1.785M |
| December 31, 2021 | 1.849M |
| September 30, 2021 | 1.491M |
| June 30, 2021 | 1.106M |
| March 31, 2021 | 1.127M |
| December 31, 2020 | 1.096M |
| September 30, 2020 | 0.336M |
| June 30, 2020 | 1.108M |
| March 31, 2020 | 0.941M |
| December 31, 2019 | 1.729M |
| September 30, 2019 | 0.921M |
| June 30, 2019 | 1.289M |
| March 31, 2019 | 1.426M |
| December 31, 2018 | 1.636M |
| September 30, 2018 | 1.226M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.951M |
| March 31, 2018 | 2.499M |
| December 31, 2017 | 2.394M |
| September 30, 2017 | 3.004M |
| June 30, 2017 | 2.992M |
| March 31, 2017 | 4.975M |
| December 31, 2016 | 2.863M |
| September 30, 2016 | 3.96M |
| June 30, 2016 | 5.247M |
| March 31, 2016 | 4.127M |
| December 31, 2015 | 4.637M |
| September 30, 2015 | 4.352M |
| June 30, 2015 | 6.048M |
| March 31, 2015 | 3.963M |
| December 31, 2014 | 2.999M |
| September 30, 2014 | 3.14M |
| June 30, 2014 | 4.674M |
| March 31, 2014 | 4.292M |
| December 31, 2013 | 5.073M |
| September 30, 2013 | 4.123M |
| June 30, 2013 | 4.15M |
| March 31, 2013 | 3.72M |
| December 31, 2012 | 4.013M |
| September 30, 2012 | 3.555M |
| June 30, 2012 | 3.224M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.336M
Minimum
Sep 2020
2.983M
Maximum
Mar 2023
1.928M
Average
1.817M
Median
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 12.03M |
| Retractable Technologies Inc | 0.1747M |
| InfuSystems Holdings Inc | -- |
| Xtant Medical Holdings Inc | 0.701M |
| Catheter Precision Inc | 0.063M |